Drug developer rattles tin for another cash dollop
MELBOURNE: Neurological diseases drug development company Actinogen Medical, capitalised at $95 million on the ASX,… read more
Dementia rates to double by 2054 claims lobby group
CANBERRA: The number of Australians with dementia is expected to nearly double by 2054, according… read more
VAD access push for dementia underway via advocates
CANBERRA: Former chief scientist Ian Chubb has called for dementia sufferers to be allowed access… read more
Hawthorndale Care Village on track to hit funding target
INVERCARGILL: A decade after the idea was raised, a care village focussed on allowing dementia… read more
